Welcome to our dedicated page for Zoetis news (Ticker: ZTS), a resource for investors and traders seeking the latest updates and insights on Zoetis stock.
Zoetis Inc. (NYSE: ZTS) is described as the world’s leading animal health company, and the ZTS news feed on Stock Titan brings together company announcements, regulatory updates and product developments that shape its story. Zoetis focuses on medicines, vaccines, diagnostics and technologies for animals, serving veterinarians, pet owners and livestock producers in over 100 countries.
News items for Zoetis often highlight its research and development activities and regulatory milestones. Recent releases include Health Canada approval for Portela (relfovetmab injection) to alleviate pain associated with osteoarthritis in cats and European Commission marketing authorization for Lenivia (izenivetmab) to reduce osteoarthritis pain in dogs. These updates illustrate Zoetis’ emphasis on monoclonal antibody therapies and long-acting pain management solutions for companion animals.
Investors can also follow financial and capital markets news, such as announcements of convertible senior notes offerings, senior notes issuances and the use of proceeds for share repurchases and capped call transactions. The company regularly reports dividends declared by its board of directors and provides quarterly and annual financial results through press releases and Form 8-K filings.
Zoetis participates in major healthcare conferences and hosts webcasts, including innovation-focused events that discuss its pipeline across chronic kidney disease, oncology, cardiology, osteoarthritis pain and dermatology. These events, along with earnings calls and conference presentations, are frequently covered in the news stream.
By monitoring the ZTS news page, readers can review product approvals, R&D updates, capital allocation decisions, credit facility arrangements and governance developments reported by Zoetis. This page can be revisited to see how new therapies, financial actions and strategic communications are disclosed over time.
Zoetis (NYSE:ZTS) announced that CEO Kristin Peck will participate in a fireside chat at the KeyBanc Capital Markets Healthcare Forum on March 17, 2026 at 10:30 a.m. ET. Interested parties can listen via a live audio webcast with a replay available on the company website.
Zoetis (NYSE:ZTS) announced that Wetteny Joseph, Executive Vice President and Chief Financial Officer, will appear in fireside chats at two investor conferences on March 9–10, 2026.
The events are the Leerink Global Healthcare Conference on March 9 at 3:00 p.m. ET and the Barclays 28th Annual Global Healthcare Conference on March 10 at 9:30 a.m. ET; live audio webcasts and replays will be available via the company's investor website.
Zoetis (NYSE: ZTS) will acquire Neogen's animal genomics business for $160 million, enhancing its Precision Animal Health capabilities.
The purchase adds five global laboratories, expanded genotyping and sequencing platforms, and software tools; Zoetis expects to close in the second half of 2026, subject to regulatory approvals and customary closing conditions.
Zoetis (NYSE:ZTS) will participate in the Bank of America Securities 2026 Animal Health Summit on Thursday, February 26, 2026 at 1:15 p.m. ET.
Wetteny Joseph, executive vice president and chief financial officer, will represent the company. According to Zoetis, a live audio webcast will be available at the company investor events page and a replay will follow after the event.
Zoetis (NYSE: ZTS) reported Q4 2025 revenue of $2.4B (+3% reported, +4% organic) and Q4 net income of $603M ($1.37 diluted). Full-year 2025 revenue was $9.5B (+2% reported, +6% organic) with net income $2.7B ($6.02 diluted).
Adjusted 2025 EPS: $6.41. 2026 guidance: revenue $9.825–$10.025B, adjusted EPS $7.00–$7.10, and expected 3–5% organic revenue growth.
Zoetis (NYSE:ZTS) declared a second-quarter 2026 cash dividend of $0.53 per share. The dividend will be paid on June 2, 2026 to holders of record at the close of business on April 20, 2026.
Zoetis (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. ET on Thursday, February 12, 2026 to review fourth-quarter and full-year 2025 financial results.
CEO Kristin Peck and EVP & CFO Wetteny Joseph will present and take questions from financial analysts. Investors and the public can access the live webcast at http://investor.zoetis.com/events-presentations. Pre-registration opens today, and a replay will be available on February 12, 2026.
Zoetis (NYSE:ZTS) will participate in the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026. Kristin Peck, CEO, and Wetteny Joseph, EVP and CFO, will present and answer analyst questions at 10:30 a.m. PT. Investors can listen to a live audio webcast at the company's investor site and access a replay on the Zoetis website after the event.
Zoetis (NYSE: ZTS) priced $1.75 billion of 0.25% convertible senior notes due 2029, with a $250 million option for additional notes, and expects the offering to close on December 18, 2025. Net proceeds are estimated at approximately $1,723.2 million (or $1,969.6 million if option exercised).
Zoetis intends to use proceeds to fund capped calls (~$163.3 million), purchase ~2.1 million shares for ~$250.3 million now, and repurchase approximately $1.6 billion of common stock (or ~$1.8 billion if option exercised) by Q1 2026.
Key terms: 0.25% coupon, maturity June 15, 2029, initial conversion price ~$148.20 (22.5% premium), cap price for capped calls $211.7150 (75% premium).
Zoetis (NYSE: ZTS) intends to offer $1.75 billion aggregate principal amount of convertible senior notes due June 15, 2029, with an initial purchaser option for an additional $250 million. Net proceeds are expected to fund (i) capped call transactions, (ii) privately negotiated repurchases of common stock and (iii) additional share repurchases to be completed by no later than the first quarter of 2026. Repurchases will be made under the company’s existing $6 billion repurchase program. Capped calls are expected to limit dilution, while option counterparties may hedge by buying or trading Zoetis stock, which could affect market price.